Evidence map›Paper›PMID 37806431›Full record

ArticleNeuroscience letters2023

Systemic administration of NIS-lncRNA antisense oligonucleotide alleviates neuropathic pain.

Tolga Berkman, Xiang Li, Yingping Liang, Anna Korban, Alex Bekker, Yuan-Xiang Tao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tolga BerkmanDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA.
Xiang LiDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA.
Yingping LiangDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA.
Anna KorbanDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA.
Alex BekkerDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA.
Yuan-Xiang TaoDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA; Department of Physiology, Pharmacology & Neuroscience, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA; Department of Cell Biology & Molecular Medicine, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark NJ07103, USA. Electronic address: yuanxiang.tao@njms.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

Discovery and validation of a new long noncoding RNA as a novel target for neuropathic painRF1NS113881 · NINDS · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DAVIDSON, STEVE, TAO, YUAN-XIANG · 2019 to 2019
$3.5M
Role of dorsal root ganglion FTO, a RNA demethylase, in neuropathic painR01NS111553 · NINDS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI TAO, YUAN-XIANG · 2019 to 2023
$2.5M
NINDS NIH HHS R01 NS111553NINDS NIH HHS RF1 NS113881
6 · The paper itself

Abstract

objectiveThe antisense oligonucleotide (ASO) is an FDA-approved strategy in the treatment of neurological diseases. We have shown the viability of using intrathecal ASO to suppress nerve injury-specific long noncoding RNA (NIS-lncRNA) in dorsal root ganglion (DRG), resulting in a stable and long-lasting antinociceptive effect on NP. This study examined whether systemic administration of NIS-lncRNA ASO relieved the chronic constriction injury (CCI)-induced nociceptive hypersensitivity.

methodsA single subcutaneous injection of NIS-lncRNA ASO at a dose of 1,000 µg was carried out 7 days after CCI or sham surgery in male mice. Behavioral tests were performed one day before surgery and at different days after surgery. DRG and spinal cord were finally collected for quantitative real-time RT-PCR and Western blot assays.

resultsNIS-lncRNA ASO significantly alleviated CCI-induced mechanical allodynia, heat hyperalgesia, and cold hyperalgesia starting on day 14 or 21 post-ASO injection and lasting for at least 7 days on the ipsilateral side. Additionally, CCI-induced spontaneous pain and ipsilateral dorsal horn neuronal and astrocyte hyperactivation were blocked on day 28 after NIS-lncRNA ASO injection. As predicted, the CCI-induced increases in the levels of NIS-lncRNA and its downstream target C-C motif chemokine ligand 2 in the ipsilateral lumbar 3 and 4 DRGs were attenuated on day 28 following NIS-lncRNA ASO injection.

conclusionOur findings indicate that systemic administration of NIS-lncRNA ASO also produces a stable and long-lasting antinociceptive effect on neuropathic pain. NIS-lncRNA ASO may have potential clinical application in the treatment of this disorder.

Indexed as

Chronic PainNeuralgiaRNA, Long NoncodingAnalgesicsAnimalsGanglia, SpinalHyperalgesiaMaleMiceOligonucleotides, AntisenseRatsRats, Sprague-DawleySpinal Cord Dorsal HornAnalgesicsOligonucleotides, AntisenseRNA, Long NoncodingAntisense oligonucleotidesDorsal root ganglionNerve injury-specific long noncoding RNANerve traumaNeuropathic painSystemic administration

Identifiers

PMID37806431
PMCPMC10842954
OpenAlexW4387398507

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.